GBLX (GB Sciences) OCF Margin %: -127.84% (As of Dec. 2024)


What is GB Sciences OCF Margin %?

GB Sciences GBLX OCF Margin % is -127.84% as of Dec. 2024.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. GB Sciences's Cash Flow from Operations for the three months ended in Dec. 2024 was $-0.12 Mil. GB Sciences's Revenue for the three months ended in Dec. 2024 was $0.10 Mil. Therefore, GB Sciences's OCF Margin % for the quarter that ended in Dec. 2024 was -127.84%.

As of today, GB Sciences's current OCF Yield % is -414.75%.

The historical rank and industry rank for GB Sciences's OCF Margin % or its related term are showing as below:

GBLX' s OCF Margin % Range Over the Past 10 Years
Min: -487.97   Med: -285.27   Max: -143.54
Current: -521.65

During the past 13 years, the highest OCF Margin % of GB Sciences was -143.54%. The lowest was -487.97%. And the median was -285.27%.

GBLX's OCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -65.71 vs GBLX: -521.65

GB Sciences OCF Margin % Related Terms

GB Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for GB Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GB Sciences OCF Margin % Chart

GB Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -143.54 0.00 0.00 0.00 0.00

GB Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -127.84

GBLX vs QRON, ENDV, CNBX: OCF Margin % Comparison

For the Biotechnology subindustry, GB Sciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GB Sciences OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's OCF Margin % distribution charts can be found below:

* The bar in red indicates where GB Sciences's OCF Margin % falls into.


GB Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

GB Sciences's OCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-0.976/0
= %

GB Sciences's OCF Margin for the quarter that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-0.124/0.097
=-127.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -127.84% mean?
GB Sciences (GBLX) has a OCF Margin % of -127.84% as of Dec. 2024. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GB Sciences and its competitors.
Is GB Sciences' OCF Margin % too high?
GB Sciences' current OCF Margin % is -127.84%.
How does GB Sciences' OCF Margin % compare to QRON and ENDV?
GB Sciences' OCF Margin % of -127.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on GB Sciences and its competitors. GB Sciences's current OCF Margin % is -127.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GB Sciences stock overvalued right now?
GB Sciences (GBLX) has a current OCF Margin % of -127.84%. The current OCF Margin % is -127.84%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For GB Sciences (GBLX), the current OCF Margin % is -127.84% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GB Sciences Business Description

Address 9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments. The company's intellectual property covers various medical conditions, from which five drug development programs are in the preclinical stage of drug development including its formulations for Parkinson's disease (PD), chronic pain, cytokine release syndrome, depression, and cardiovascular therapeutic programs.